Fulltext

Long-term survival and interruption of HAART in HIV-related pulmonary hypertension

Zinkernagel, A. ; von Overbeck, J. ; Opravil, M. ; Jenni, R. ; Speich, R. ; Mueller, N.

In: European Journal of Clinical Microbiology and Infectious Diseases, 2005, vol. 24, no. 2, p. 153-155

Aggiungi alla tua lista
    Titre
    • Long-term survival and interruption of HAART in HIV-related pulmonary hypertension
    Auteur
    • Zinkernagel, A.. Division of Infectious Diseases, Department of Medicine, University Hospital, RAE U 74, Rämistrasse 100, 8091, Zurich, Switzerland
    • von Overbeck, J.. Division of Infectious Diseases, Department of Medicine, University Hospital, RAE U 74, Rämistrasse 100, 8091, Zurich, Switzerland
    • Opravil, M.. Division of Infectious Diseases, Department of Medicine, University Hospital, RAE U 74, Rämistrasse 100, 8091, Zurich, Switzerland
    • Jenni, R.. Division of Cardiology, Department of Internal Medicine, University Hospital, Rämistrasse 100, 8091, Zurich, Switzerland
    • Speich, R.. Pulmonary Division, University Hospital, Rämistrasse 100, 8091, Zurich, Switzerland
    • Mueller, N.. Division of Infectious Diseases, Department of Medicine, University Hospital, RAE U 74, Rämistrasse 100, 8091, Zurich, Switzerland
    Type de document
    • Postprint
    Langue
    • Inglese
    Publié dans
    • European Journal of Clinical Microbiology and Infectious Diseases, 2005, vol. 24, no. 2, p. 153-155. Springer-Verlag; http://www.springer.de
    Autre version électronique
    Classification
    • Santé
    Identifiant OAI-PMH
    • oai:doc.rero.ch:312308
    Summary
    Reported here is a case of a patient with pulmonary arterial hypertension related to HIV (PAHRH) in which lipodystrophy necessitated interruption of highly active antiretroviral therapy (HAART) and long-term survival was the outcome. Although previous studies have suggested antiretroviral therapy may benefit patients with this rare complication of HIV infection, no worsening of PAHRH was observed when HAART was interrupted. Clinical and echocardiographic parameters remained stable during 7 months of follow up. In cases in which HAART is associated with relevant toxicity, interruption of HAART in patients with PAHRH can be considered, but should be used only if no alternatives are available. Close follow-up is warranted